Project UpdateJul 10, 2026, 07:31 AM
PMGC Subsidiary NorthStrive Initiates EL-22 FACS Study
AI Summary
PMGC Holdings Inc.'s subsidiary, NorthStrive Biosciences, announced plans to initiate an independent flow cytometry (FACS) analysis program for its engineered probiotic therapeutic candidate, EL-22. The study aims to quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against previously manufactured material. This work is intended to strengthen EL-22's product identity and manufacturing consistency, supporting its development to preserve muscle during weight loss, including with GLP-1 receptor agonists.
Key Highlights
- NorthStrive Biosciences to initiate independent flow cytometry (FACS) analysis for EL-22.
- Study will quantify latent myostatin antigen expression on engineered Lactobacillus casei.
- Aims to establish comparability against previously manufactured EL-22 material.
- Intends to strengthen EL-22 product identity and manufacturing consistency.
- Supports future analytical method development and regulatory readiness for EL-22.
- EL-22 is an engineered probiotic designed to preserve muscle during weight loss.
Price Impact
More from ELAB